Drug Trial Radar · NCT04675294
Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)
Last checked: Nov 19, 2026Latest source record: Aug 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
189
Actual
Start
Apr 2, 2021
Primary completion
Mar 3, 2025
Study completion Jun 30, 2026
Sponsor
- Lead sponsor
- ALX Oncology Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Dec 19, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 2 Study of evorpacept (ALX148) in Combination With pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma.
Conditions
- Head and Neck Cancer
- Head and Neck Squamous Cell Carcinoma
Interventions
evorpaceptDrug
IV Q3W
pembrolizumabDrug
IV Q3W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate per RECIST 1.1Time frame: Last randomized patient reaching at least 24 weeks of follow-up
Locations
53 sites in 9 countries. Site status is shown where the registry gives one.
Hoag Hospital
Irvine, California
University of California San Diego
La Jolla, California
H. Lee Moffitt Cancer Center
Tampa, Florida
Northwest Georgia Oncology Centers
Marietta, Georgia
Rush University Medical Center
Chicago, Illinois
Blessing Cancer Center
Quincy, Illinois
University of Maryland Medical System
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Rutgers Cancer Institute of New Jersey
Newark, New Jersey
Memorial Sloan-Kettering Cancer Center
Long Island City, New York
The Ohio State University
Columbus, Ohio
Oregon Health & Science University
Portland, Oregon
Vanderbilt - Ingram Cancer Center
Nashville, Tennessee
Houston Methodist Cancer Center
Houston, Texas
Ashford Cancer Centre Research
Windsor Gardens, Australia
St. Vincent's
Sydney, New South Wales, Australia
Royal Brisbane and Womens Hospital
Brisbane, Queensland, Australia
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Sir Charles Gairdner Hospital
Perth, Western Australia, Australia
Cliniques Universitaires Saint-Luc
Brussels, Belgium
AZ Groeninge
Kortrijk, Belgium
UZ Leuven
Leuven, Belgium
Hamilton Health Sciences - Juravinski Cancer Centre
Hamilton, Ontario, Canada
LHSC - Victoria Hospital
London, Ontario, Canada
Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
VUMC Goederenontvangst
Amsterdam, Netherlands
Universitair Medisch Centrum Groningen
Groningen, Netherlands
National University Cancer Institute
Singapore, Singapore
National Cancer Centre Singapore
Singapore, Singapore
Chungbuk National University Hospital
Cheongju-si, South Korea
Yeungnam University Medical Center
Daegu, South Korea
Chungnam National University Hospital
Daejeon, South Korea
CHA University of Bundang
Gyeonggi-do, South Korea
Gachon University - Gil Medical Center
Incheon, South Korea
Seoul National University Bundang Hospital
Seongnam, South Korea
Korea University Medical Center (KUMC) - Korea University Anam Hospital
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
The Catholic University of Korea - Eunpyeong St. Mary's Hospital
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.